¹⁸F-fluorodeoxyglucose PET in Major Psychiatric Disorders.

Authors

Rodolfo Ferrando, Artur Martins Coutinho

Published in

PET clinics. Jun 30, 2026. Epub Jun 30, 2026.

Abstract

¹⁸F-fluorodeoxyglucose (FDG)-PET offers a systems-level view of brain dysfunction in psychiatry, with findings more informative at the circuit and network level than as fixed disease-specific patterns. In schizophrenia, addictions, and mood disorders, reproducible abnormalities involve prefrontal, limbic, striatal, and multimodal associative networks, although their expression depends on clinical state, stage, treatment, and comorbidity. This review summarizes principal FDG-PET findings in major psychiatric disorders and integrates them with selected molecular imaging data. Although FDG-PET is not a diagnostic test for primary psychiatric disorders, it aids in complex cases by supporting phenotyping and distinguishing psychiatric illness from neurodegenerative and other brain disorders.

PMID:
42379930
Bibliographic data and abstract were imported from PubMed on 01 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.